Dabur Sells Anticancer Business
Indian company Dabur India has sold its pharmaceutical division to German healthcare firm Fresenius Kabi. The asset mainly sells generic anticancer agents, and the purchase price was INR872 crore (US$219mn). BMI believes Dabur's real motivation behind the transaction was to focus on its core competency of fast-moving consumer goods (FMCGs), rather than the official line. According to Dabur's founder and director, Anand Burman, Fresenius is much better equipped in terms of international marketing capabilities to realise the full potential of the division. By not selling, Dabur would have being doing a 'disservice to the shareholders', he added.
Comments